Novo Nordisk has launched its Wegovy weight-loss pill in the US at a significantly lower price than injectable alternatives. The once-daily pill is the first and only GLP-1 tablet on the market and recently received regulatory approval. Self-paying patients can access the starting dose for $149 a month, far below typical injection prices. The pill offers a needle-free option that may appeal to more patients. The move accelerates a price war with rivals including Eli Lilly, which sells competing injections. Novo hopes the launch will help regain market share after recent profit warnings. The Wegovy pill is currently approved only in the US, with a UK decision expected later this year.
Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
Important Links
© 2026 Paris Paper. All Rights Reserved.